Search for: "Sanofi GmbH"
Results 1 - 20
of 72
Sorted by Relevance
|
Sort by Date
2 Aug 2023, 11:05 am
Sanofi further argued that the Board improperly shifted the burden of persuasion from Mylan to prove that the challenged claims were unpatentable to Sanofi to defend the claims of the ’614 patent as patentable. [read post]
12 Aug 2019, 12:32 am
Sanofi-Aventis Deutschland Gmbh). [read post]
30 Apr 2014, 10:00 pm
The Federal Circuit decision in Sanofi-Aventis Deutschland GmbH v. [read post]
24 May 2009, 10:58 pm
The opposing party, Sanofi-Aventis Deutschland GmbH, was represented by McDonnell Boehnen Hulbert & Berghoff LLP, of Chicago. [read post]
29 Dec 2021, 4:16 pm
The outcome For the foregoing reasons, we affirm the four final written decisions that determined unpatentability based on Steenfeldt-Jensen: IPR2018-01670, IPR2018-01676, IPR2018-01678, and IPR2019-00979. [read post]
9 Jun 2008, 4:50 am
Sanofi-Aventis Deutschland GMBH et al. 2:08-cv-00258; filed June 5, 2008 in the Eastern District of Virginia Declaratory judgment of non-infringement and invalidity of U.S. [read post]
15 Jul 2008, 4:57 am
The patent was opposed by several companies involved in commercializing RNA interference (RNAi), including Sanofi-Aventis Deutschland GmbH, Sirna Therapeutics, Nucleonics, Inc., Quark Biotech, and Silence Therapeutics AG. [read post]
25 May 2023, 6:00 am
In Sanofi-Aventis Deutschland GMBH v. [read post]
6 Nov 2022, 8:53 am
Sanofi. [read post]
5 Feb 2018, 9:59 pm
Sanofi Aventis Deutschland GmbH PTAB Petition: IPR2017-01526; filed June 5, 2017. [read post]
24 Apr 2014, 9:59 pm
By Michael Greenfield -- On April 21, 2014, a Federal Circuit panel reiterated its interpretation and application to the chemical arts of the KSR obviousness standard. [read post]
22 Apr 2014, 7:41 am
United Parcel Serv., Inc., 665 F.3d 68, 73 (3d Cir. 2012).Sanofi-Aventis Deutschland GMBH at *12.Jury InstructionsYou may make an adverse inference in this case against Glenmark. [read post]
21 Apr 2014, 2:03 pm
According to the case, Sanofi-Aventis Deutschland GmbH is the owner of the patent at issue and Aventis Pharma S.A. is the exclusive licensee of that patent. [read post]
11 May 2023, 10:12 am
By Chris Holman Sanofi-Aventis Deutschland GMBH v. [read post]
6 Oct 2017, 2:34 pm
Mass. 2013) and Abbvie Deutschland GmbH v. [read post]
6 Oct 2017, 2:34 pm
Mass. 2013) and Abbvie Deutschland GmbH v. [read post]
27 Sep 2020, 6:36 pm
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
12 Mar 2015, 11:09 am
Today's the day that many pharmaceutical patent term extension-watchers have been waiting for with feelings of optimism or anxiety: the day on which the Court of Justice of the European Union (CJEU) delivered its ruling in Case C‑577/13, Actavis Group PTC EHF, Actavis UK Ltd v Boehringer Ingelheim Pharma GmbH & Co. [read post]
5 Oct 2020, 10:25 am
., No. 19-1452; Sanofi-Aventis Deutschland GmbH v. [read post]
15 Mar 2011, 3:52 pm
Judge Susan Illston recently granted summary judgment on a few claims but left others for trial in a massive pharmaceutical patent case between Sanofi-Aventis Deutchland GMBH (Sanofi, plaintiff), Genentech, Inc. [read post]
